2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T4c3,A total of 401 patients (214 [53.4%] women) with 403 non-LM/non-ALM MIS and a median (IQR) age of 52 (40-62) years were included in the analysis. MIS was frequently located on the trunk (201 lesions [49.9%]), followed by the lower extremity (99 [24.6%]), the upper extremity (71 [17.6%]), and the head and neck (32 [7.9%]). All lesions were initially treated with excisional biopsy, followed by wide excision for 372 (92.3%). There was only 1 local recurrence in a patient with involved margins at the excisional biopsy who did not undergo wide excision and developed an invasive melanoma 14 months later. Thirty lesions in 30 patients had clear excisional biopsy margins with no wide excision and had no recurrence at a median (IQR) follow-up of 8.1 (4.1-12.9) years. In 23 patients with 23 lesions that had wide excision with narrower than the standard 0.5-cm margins (mean [SD] margin size, 0.36 [0.07] cm), no recurrences were found at a median (IQR) follow-up of 4.3 (2.7-6.2) years. During follow-up, 6 patients (1.5%) developed a lesion suspicious for recurrence near the excision scar, which was excised and showed nevus or solar lentigo on histopathology. No patients had metastasis or melanoma-specific death.31:T9c8,The overdiagnosis of melanoma in situ (MIS) is well documented. There is limited evidence on the rate of local recurrence of the non-lentigo maligna (non-LM)/non-acral lentiginous melanoma (non-ALM) subtypes. To investigate local recurrence and prognosis in non-LM/non-ALM MIS, the histopathological clearance of the excisional biopsy margins, and the association with the size of wide excision margins. This retrospective cohort study included patients with non-LM/non-ALM MIS diagnosed from 1991 to 2023 who were followed up for at least 1 year at the Skin Cancer and Melanoma Unit of Andreas Sygros University Hospital in Athens, Greece. Patients with a history of invasive melanoma or a histopathological diagnosis of LM or ALM in situ were excluded. Median (IQR) follow-up was 5.2 (2.9-7.9) years. Deidentified data on patient demographics and clinical characteristics, including the histopathological clearance of margins of the initial excisional biopsy and the size of margins of the wide excision, were obtained from medical records. The primary outcomes were local recurrence, metastasis, and melanoma-specific survival. A total of 401 patients (214 [53.4%] women) with 403 non-LM/non-ALM MIS and a median (IQR) age of 52 (40-62) years were included in the analysis. MIS was frequently located on the trunk (201 lesions [49.9%]), followed by the lower extremity (99 [24.6%]), the upper extremity (71 [17.6%]), and the head and neck (32 [7.9%]). All lesions were initially treated with excisional biopsy, followed by wide excision for 372 (92.3%). There was only 1 local recurrence in a patient with involved margins at the excisional biopsy who did not undergo wide excision and developed an invasive melanoma 14 months later. Thirty lesions in 30 patients had clear excisional biopsy margins with no wide excision and had no recurrence at a median (IQR) follow-up of 8.1 (4.1-12.9) years. In 23 patients with 23 lesions that had wide excision with narrower than the standard 0.5-cm margins (mean [SD] margin size, 0.36 [0.07] cm), no recurrences were found at a median (IQR) follow-up of 4.3 (2.7-6.2) years. During follow-up, 6 patients (1.5%) developed a lesion suspicious for recurrence near the excision scar, which was excised and showed nevus or solar lentigo on histopathology. No patients had metastasis or melanoma-specific death. This cohort study found that diagnostic excisional biopsies with clear margins may be sufficient for treating MIS; however, larger studies are necessary.32:Tc23,ImportanceThe overdiagnosis of melanoma in situ (MIS) is well documented. There is limited evidence on the rate of local recurrence of the non-lentigo maligna (non-LM)/non-acral lentiginous melanoma (non-ALM) subtypes.ObjectiveTo investigate local recurrence and prognosis in non-LM/non-ALM MIS, the histopathological clearance of the excisional biopsy margins, and the association with the size of wide excision margins.Design, Setting, and ParticipantsThis retrospective cohort study included patients with non-LM/non-ALM MIS diagnosed from 1991 to 2023 who were followed up for at least 1 year at the Skin Cancer and Melanoma Unit of Andreas Sygros University Hospital in Athens, Greece. Patients with a history of invasive melanoma or a histopathological diagnosis of LM or ALM in situ were excluded. Median (IQR) follow-up was 5.2 (2.9-7.9) years. Deidentified data on patient demographics and clinical characteristics, including the histopathological clearance of margins of the initial excisional biopsy and the size of margins of the wide excision, were obtained from medical records.Main Outcomes and MeasuresThe primary outcomes were local recurrence, metastasis, and melanoma-specific survival.ResultsA total of 401 patients (214 [53.4%] women) with 403 non-LM/non-ALM MIS and a median (IQR) age of 52 (40-62) years were included in the analysis. MIS was frequently located on the trunk (201 lesions [49.9%]), followed by the lower extremity (99 [24.6%]), the upper extremity (71 [17.6%]), and the head and neck (32 [7.9%]). All lesions were initially treated with excisional biopsy, followed by wide excision for 372 (92.3%). There was only 1 local recurrence in a patient with involved margins at the excisional biopsy who did not undergo wide excision and developed an invasive melanoma 14 months later. Thirty lesions in 30 patients had clear excisional biopsy margins with no wide excision and had no recurrence at a median (IQR) follow-up of 8.1 (4.1-12.9) years. In 23 patients with 23 lesions that had wide excision with narrower than the standard 0.5-cm margins (mean [SD] margin size, 0.36 [0.07] cm), no recurrences were found at a median (IQR) follow-up of 4.3 (2.7-6.2) years. During follow-up, 6 patients (1.5%) developed a lesion suspicious for recurrence near the excision scar, which was excised and showed nevus or solar lentigo on histopathology. No patients had metastasis or melanoma-specific death.Conclusions and RelevanceThis cohort study found that diagnostic excisional biopsies with clear margins may be sufficient for treating MIS; however, larger studies are necessary.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Melanoma In Situ: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Melanoma In Situ (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Melanoma%20In%20Situ\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Melanoma In Situ\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Melanoma%20In%20Situ\"}]}}"}}]],["$","$L2f",null,{"title":"Melanoma In Situ: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Melanoma In Situ with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1097/dss.0000000000005309","pmid":"42574237","title":"An 18-year Review of Melanonychia and Nail Melanoma Risk in Singapore","journal_title":"Dermatologic Surgery","journal_issn":"1076-0512","published_at":"2026-08-11T00:00:00.000Z","url":"https://doi.org/10.1097/dss.0000000000005309","source_score":1,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-19T06:28:56.383Z","updated_at":"2026-08-19T06:28:56.383Z","tags":[{"paper_doi":"10.1097/dss.0000000000005309","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005309","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005309","tag_type":"condition","value":"Longitudinal Melanonychia","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005309","tag_type":"condition","value":"Melanoma In Situ","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005309","tag_type":"condition","value":"Nail Apparatus Melanoma","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005309","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005309","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005309","tag_type":"sample_size","value":"n=1556","value_numeric":1556},{"paper_doi":"10.1097/dss.0000000000005309","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005309","tag_type":"study_design","value":"Retrospective Observational Study","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005309","tag_type":"warning","value":"Blue-collar occupation as a predictor is epidemiologically novel and biologically unconfirmed — clinicians should note this may reflect a confounding factor rather than a causal risk.","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005309","tag_type":"warning","value":"Only 198 of 1,556 patients underwent biopsy; referral and biopsy selection criteria are not fully defined, which may affect the reported 4.0% NAM prevalence.","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005309","tag_type":"warning","value":"The cohort is predominantly Chinese (80.7%) from a single Singapore centre; findings may not generalise to other Asian or non-Asian populations.","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005309","tag_type":"warning","value":"The NAM case count is very small (n=8), so predictor associations (age, occupation) should be interpreted cautiously.","value_numeric":null}],"summaries":{"what_studied":"A retrospective observational study of 1,556 patients with longitudinal melanonychia (LM) seen at the National Skin Centre, Singapore (2004–2021), characterizing demographics and clinical features, identifying predictors of nail apparatus melanoma (NAM), and analyzing nail unit biopsy outcomes.","key_result":"Of 198 biopsied patients, 8 (4.0%) had NAM, including 3 melanoma in situ. All invasive NAM cases showed nail plate destruction, nail bed ulceration, and positive Hutchinson sign. Age ≥50 years (p=.001) and blue-collar occupation (p=.049) were significantly associated with malignancy. Post-biopsy complications occurred in 20.7%, most commonly nail dystrophy.","limitations":"Single-centre retrospective design limits generalisability; only 274 of 1,556 patients were referred for biopsy, introducing selection bias; small NAM case count (n=8) constrains statistical power for predictor analysis.","practice_takeaway":"In patients with longitudinal melanonychia, prioritize biopsy when the patient is aged ≥50, works in a blue-collar occupation, or has monodactylous involvement — especially if nail plate destruction or Hutchinson sign is present. Post-biopsy nail dystrophy is common and should be discussed in pre-procedure counselling."}},{"doi":"10.1097/cmr.0000000000001109","pmid":"42166631","title":"Pregnancy and risk of melanoma: a matched retrospective cohort study","journal_title":"Melanoma Research","journal_issn":"0960-8931","published_at":"2026-06-24T00:00:00.000Z","url":"https://doi.org/10.1097/cmr.0000000000001109","source_score":1,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-02T13:33:25.581Z","updated_at":"2026-07-02T13:33:25.581Z","tags":[{"paper_doi":"10.1097/cmr.0000000000001109","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1097/cmr.0000000000001109","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1097/cmr.0000000000001109","tag_type":"condition","value":"Melanoma","value_numeric":null},{"paper_doi":"10.1097/cmr.0000000000001109","tag_type":"condition","value":"Melanoma In Situ","value_numeric":null},{"paper_doi":"10.1097/cmr.0000000000001109","tag_type":"condition","value":"Pregnancy-Associated Melanoma","value_numeric":null},{"paper_doi":"10.1097/cmr.0000000000001109","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1097/cmr.0000000000001109","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1097/cmr.0000000000001109","tag_type":"modality","value":"Obstetric/Gestational Exposure","value_numeric":null},{"paper_doi":"10.1097/cmr.0000000000001109","tag_type":"sample_size","value":"n=1708386","value_numeric":1708386},{"paper_doi":"10.1097/cmr.0000000000001109","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1097/cmr.0000000000001109","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1097/cmr.0000000000001109","tag_type":"warning","value":"Study population is drawn from the TriNetX network, which may not be globally representative depending on participating site distribution.","value_numeric":null},{"paper_doi":"10.1097/cmr.0000000000001109","tag_type":"warning","value":"Sun exposure and dermatologic surveillance were controlled via proxy variables only — residual confounding cannot be excluded.","value_numeric":null},{"paper_doi":"10.1097/cmr.0000000000001109","tag_type":"warning","value":"The comparator group (non-pregnant females on contraceptive management) may not perfectly represent the general reproductive-age female population, potentially introducing selection bias.","value_numeric":null}],"summaries":{"what_studied":"This retrospective cohort study used the TriNetX Global Collaborative Network to compare incident melanoma risk in pregnant patients (n=854,193) versus propensity-score matched non-pregnant reproductive-age females on contraceptive management, over a 21-month window (pregnancy plus 1 year postpartum).","key_result":"Pregnancy was not associated with increased risk of invasive melanoma (HR 0.92, 95% CI 0.78–1.07) or melanoma in situ (HR 1.01, 95% CI 0.82–1.24); a sensitivity analysis restricted to prior estrogen-based therapy users (n=128,716/cohort) confirmed null findings (invasive HR 1.06, 95% CI 0.76–1.49; MIS HR 1.05, 95% CI 0.67–1.65).","limitations":"- Retrospective design using real-world EHR/claims data limits causal inference and may miss melanoma diagnoses outside the network.\n- Propensity-score matching on sun exposure and dermatologic surveillance used proxy variables, which may not fully control for these key confounders.\n- The 21-month observation window may be insufficient to capture melanomas with longer latency.","practice_takeaway":"Clinicians can reassure pregnant patients that pregnancy itself does not appear to independently increase melanoma risk. Routine dermatologic surveillance recommendations for reproductive-age women should not differ based on pregnancy status alone."}},{"doi":"10.1097/dss.0000000000005174","pmid":"42160516","title":"Imiquimod for Melanoma in Situ and Lentigo Maligna: A Systematic Review","journal_title":"Dermatologic Surgery","journal_issn":"1076-0512","published_at":"2026-05-18T00:00:00.000Z","url":"https://doi.org/10.1097/dss.0000000000005174","source_score":1,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-02T13:27:29.995Z","updated_at":"2026-06-02T13:27:29.995Z","tags":[{"paper_doi":"10.1097/dss.0000000000005174","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005174","tag_type":"brand","value":"Aldara","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005174","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005174","tag_type":"condition","value":"Lentigo Maligna","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005174","tag_type":"condition","value":"Melanoma In Situ","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005174","tag_type":"generic","value":"imiquimod","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005174","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005174","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005174","tag_type":"modality","value":"Topical Immune Response Modifier","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005174","tag_type":"sample_size","value":"n=129","value_numeric":129},{"paper_doi":"10.1097/dss.0000000000005174","tag_type":"study_design","value":"Systematic Review","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005174","tag_type":"warning","value":"Brand tag 'Aldara' added as the most common imiquimod brand; the paper does not explicitly name a brand.","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005174","tag_type":"warning","value":"Level of evidence assigned as 3 (systematic review of heterogeneous, mostly small observational studies) rather than 1, due to lack of RCTs and small pooled sample size noted by the authors.","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005174","tag_type":"warning","value":"Sex distribution of the study population was not reported in the available text; sex tag omitted.","value_numeric":null},{"paper_doi":"10.1097/dss.0000000000005174","tag_type":"warning","value":"The full text body of the paper was not accessible — only the abstract and publisher permissions page were retrieved. All extracted data are based solely on the abstract.","value_numeric":null}],"summaries":{"what_studied":"This systematic review evaluated the efficacy, safety, and optimal treatment protocols of topical imiquimod for histologically confirmed melanoma in situ (MIS) and lentigo maligna (LM), analyzing 13 studies with 129 cases published from 2000 to 2025.","key_result":"Histological clearance was achieved in ~84.5% of cases (range 77%–90%). Treatment duration ranged from 4 to 44 weeks (most protocols 8–16 weeks). Recurrence rates ranged from 0.5% to 15%. Local erythema and irritation were common, and an inflammatory response was strongly associated with treatment success.","limitations":"- Heterogeneous treatment protocols across studies make direct comparisons difficult.\n- Small total sample size (n=129) and limited long-term follow-up reduce certainty of results.\n- No standardized dosing regimen exists, limiting generalizability.","practice_takeaway":"Topical imiquimod is a viable nonsurgical option for MIS and LM—especially in anatomically challenging areas—with an ~84.5% histological clearance rate and acceptable side effects. Monitor for local inflammatory response, which appears to predict treatment success."}},{"doi":"10.1093/bjd/ljag177","pmid":"42104605","title":"Epidemiology of lentigo maligna and lentigo maligna melanoma in England between 2013–2023","journal_title":"British Journal of Dermatology","journal_issn":"0007-0963","published_at":"2026-05-08T00:00:00.000Z","url":"https://doi.org/10.1093/bjd/ljag177","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-16T13:22:30.303Z","updated_at":"2026-05-16T13:22:30.303Z","tags":[{"paper_doi":"10.1093/bjd/ljag177","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag177","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag177","tag_type":"condition","value":"Lentigo Maligna","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag177","tag_type":"condition","value":"Lentigo Maligna Melanoma","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag177","tag_type":"condition","value":"Melanoma In Situ","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag177","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag177","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag177","tag_type":"modality","value":"Surgical Excision","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag177","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag177","tag_type":"study_design","value":"Population-Based Cohort Study","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag177","tag_type":"warning","value":"No total sample size (N) is reported in the abstract; a sample_size tag could not be assigned.","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag177","tag_type":"warning","value":"Post-2020 incidence increase is unexplained; the authors caution it may represent pandemic-related diagnostic delay rather than a true epidemiological rise.","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag177","tag_type":"warning","value":"The 'practice_changing' impact flag is applied cautiously — the low progression risk finding challenges routine surgical dogma but the authors note that untreated progression data remain incomplete.","value_numeric":null}],"summaries":{"what_studied":"This population-based study used English National Disease Registration Service data (2013–2023) to describe incidence trends, survival, and the 10-year risk of progression from lentigo maligna (LM, melanoma in situ) to lentigo maligna melanoma (LMM), along with factors that modify progression and survival.","key_result":"Age-standardised incidence rates were stable from 2013–2019 (LM ~4.91–5.03; LMM ~1.84–1.97 per 100,000 person-years), dipped in 2020, then rose above pre-pandemic levels by 2023. The 10-year cumulative risk of LM progressing to LMM was only 1.0% (95% CI 0.8–1.1%). Female sex was strongly protective against melanoma-specific death (HR 0.56, 95% CI 0.49–0.66); most patients died from other cancers or cardiovascular disease rather than melanoma.","limitations":"- Risk of progression is calculated only for untreated or undertreated LM, and outcomes without surgery remain incompletely characterised.\n- Post-2020 incidence spike may reflect delayed pandemic presentations rather than a true rise, and future data are needed to distinguish the two.\n- Pseudonymised registry data limit granular clinical detail (e.g., treatment received, lesion size, histological subtype).","practice_takeaway":"The 10-year progression risk from LM to LMM is low (~1%), and most patients die of unrelated causes — supporting shared, patient-centred decision-making for older or frailer adults who may not tolerate surgery. Head and neck location and older age identify the subset at higher progression risk who may benefit most from active treatment."}},{"doi":"10.2340/actadv.v106.44610","pmid":"41947654","title":"Predicting Melanoma Impact on the Swedish Healthcare System from the Adult Population Using Machine Learning on Registry Data","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-04-08T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.44610","source_score":180,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-07T17:34:09.741Z","updated_at":"2026-05-07T17:34:09.741Z","tags":[{"paper_doi":"10.2340/actadv.v106.44610","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.44610","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.44610","tag_type":"condition","value":"Melanoma","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.44610","tag_type":"condition","value":"Melanoma In Situ","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.44610","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.44610","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.44610","tag_type":"modality","value":"Machine Learning Risk Prediction","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.44610","tag_type":"sample_size","value":"n=6,036,186","value_numeric":6036186},{"paper_doi":"10.2340/actadv.v106.44610","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.44610","tag_type":"study_design","value":"Retrospective Cohort Study with Machine Learning Prediction Models","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.44610","tag_type":"warning","value":"AUC values are modest (0.68–0.74), suggesting the models are not yet ready for direct clinical implementation without further validation.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.44610","tag_type":"warning","value":"Ethnicity and skin phototype data are absent from Swedish registries, which may introduce fairness gaps for minority populations and limit applicability to more diverse healthcare settings.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.44610","tag_type":"warning","value":"The outcome excludes melanomas diagnosed outside Sweden, potentially underestimating true incidence and affecting model calibration.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.44610","tag_type":"warning","value":"The study design is a retrospective cohort with ML modeling; it is not a traditional RCT or diagnostic accuracy study, so level of evidence is approximate.","value_numeric":null}],"summaries":{"what_studied":"Machine learning models (logistic regression, random forests, gradient boosting, neural network) were evaluated to predict 5-year melanoma incidence (including in situ) in the entire adult Swedish population (n = 6,036,186), using registry-based predictors including demographics, ICD-10 diagnoses, and dispensed medications, with an index date of 31 December 2014 and outcome window of 2015–2019.","key_result":"Gradient boosting using all predictors achieved the best AUC of 0.735 (95% CI 0.725–0.746); dropping healthcare codes (diagnoses and medications) reduced AUC to 0.681 (95% CI 0.670–0.691). Among the top 301–400 highest-risk individuals (0.0066% of cohort), PPV reached 33% (95% CI 17–53%) versus a baseline risk of 0.64%.","limitations":"- Results derive solely from Swedish registries, limiting generalizability outside comparable Nordic healthcare systems.\n- Models use time-independent (binary occurrence) features; time-dependent patterns were not captured.\n- Outcome is defined as melanoma burdening the Swedish healthcare system, excluding diagnoses made abroad, which may undercount true incidence.","practice_takeaway":"Adding historical diagnosis and medication codes to demographic data meaningfully improves melanoma risk prediction from routine registry data. Registry-based risk stratification could help clinicians target high-risk patients for earlier follow-up, though screening expansion must be weighed against overdiagnosis risk."}},{"doi":"10.1001/jamadermatol.2025.3369","pmid":"41060662","title":"Navigating Melanoma In Situ in the Age of Overdiagnosis","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-10-08T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2025.3369","source_score":9,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-10-13","doi":"10.1001/jamadermatol.2025.3369","days":"7","issn":"2168-6068","rank":"8","field":"Clinical Medicine","score":"9","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.3369","title":"Navigating Melanoma In Situ in the Age of Overdiagnosis.","journal":"JAMA dermatology","methods":"","results":"","abstract":"This Viewpoint discusses different approaches to evaluating and managing melanoma in situ to help mitigate the potential harms of overdiagnosis.","keywords":[],"pubmed_id":"41060662","conclusions":"","publication_date":"2025-10-08T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.3369","URL":"https://doi.org/10.1001/jamadermatol.2025.3369","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2839731/jamadermatology_shaked_2025_vp_250004_1759870968.77034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Navigating Melanoma In Situ in the Age of Overdiagnosis"],"author":[{"given":"Yaelle","family":"Shaked","sequence":"first","affiliation":[{"name":"Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, NYU Langone Health, New York, New York"},{"name":"Icahn School of Medicine at Mount Sinai, New York, New York"}]},{"given":"Alyssa","family":"Swearingen","sequence":"additional","affiliation":[{"name":"Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, NYU Langone Health, New York, New York"},{"name":"Rutgers New Jersey Medical School, Newark"}]},{"given":"Jennifer A.","family":"Stein","sequence":"additional","affiliation":[{"name":"Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, NYU Langone Health, New York, New York"}]},{"given":"David","family":"Polsky","sequence":"additional","affiliation":[{"name":"Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, NYU Langone Health, New York, New York"}]}],"issued":{"date-parts":[[2025,10,8]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2025-10-08T15:01:01Z","timestamp":1759935661000,"date-parts":[[2025,10,8]]},"indexed":{"date-time":"2025-10-08T15:40:22Z","timestamp":1759938022597,"date-parts":[[2025,10,8]]},"subject":[],"abstract":"This Viewpoint discusses different approaches to evaluating and managing melanoma in situ to help mitigate the potential harms of overdiagnosis.","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2839731"}},"subtitle":[],"deposited":{"date-time":"2025-10-08T15:01:01Z","timestamp":1759935661000,"date-parts":[[2025,10,8]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,10,8]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1056/NEJMsb2019760","key":"dvp250004r1","year":"2021","issue":"1","author":"Welch","volume":"384","first-page":"72","unstructured":null,"article-title":"The rapid rise in cutaneous melanoma diagnoses.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.21750","key":"dvp250004r2","year":"2022","issue":"4","author":"Bell","volume":"187","first-page":"459","unstructured":null,"article-title":"Melanoma overdiagnosis: why it matters and what can be done about it.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2023.6158","key":"dvp250004r3","year":"2024","issue":"5","author":"Mahama","volume":"160","first-page":"495","unstructured":null,"article-title":"Lived experiences and fear of cancer recurrence among survivors of localized cutaneous melanoma.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2022.50613","key":"dvp250004r4","year":"2023","issue":"1","author":"Barnhill","volume":"6","first-page":null,"unstructured":null,"article-title":"Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis classification schema for melanocytic lesions: a consensus statement.","journal-title":"JAMA Netw Open","doi-asserted-by":"publisher"},{"DOI":"10.5826/dpc.1304a249","key":"dvp250004r5","year":"2023","issue":"4","author":"Marghoob","volume":"13","first-page":null,"unstructured":null,"article-title":"Melanoma over-diagnosis: historical perspective and the path forward.","journal-title":"Dermatol Pract Concept","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2009.09374.x","key":"dvp250004r6","year":"2009","issue":"6","author":"Menzies","volume":"161","first-page":"1270","unstructured":null,"article-title":"Impact of dermoscopy and short-term sequential digital dermoscopy imaging for the management of pigmented lesions in primary care: a sequential intervention trial.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2024.42.16_suppl.9502","key":"dvp250004r7","year":"2024","issue":"16","author":"Hong","volume":"42","first-page":"9502","unstructured":null,"article-title":"A randomised, controlled, multicentre trial of imiquimod versus radiotherapy for lentigo maligna.","journal-title":"J Clin Oncol","doi-asserted-by":"publisher"}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"reference-count":7,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10,8]]},"references-count":7,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2025.3369","is_oa":false,"title":"Navigating Melanoma In Situ in the Age of Overdiagnosis","updated":"2025-10-09T00:28:14+00:00","published_date":"2025-10-08","best_oa_location":null}},"created_at":"2025-10-14T07:02:46.938Z","updated_at":"2025-10-19T07:07:31.491Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.3369","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3369","tag_type":"condition","value":"Melanoma In Situ","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3369","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3369","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3369","tag_type":"study_design","value":"Expert Opinion/Editorial","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3369","tag_type":"warning","value":"Design classification is inferred from the article type and could differ if the full text includes additional analyses.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3369","tag_type":"warning","value":"Only a brief abstract sentence was provided; specific approaches are not detailed here.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3369","tag_type":"warning","value":"This is a Viewpoint/editorial without primary data; no quantitative results are available.","value_numeric":null}],"summaries":{"what_studied":"A Viewpoint outlines approaches to evaluating and managing melanoma in situ to reduce harms from overdiagnosis.","limitations":"As a Viewpoint, it offers expert opinion without new empirical data or quantified outcomes."}},{"doi":"10.1001/jamadermatol.2025.3078","pmid":"40900523","title":"Local Recurrence and Survival in Patients With Melanoma In Situ","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-09-03T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2025.3078","source_score":26,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-10-19","doi":"10.1001/jamadermatol.2025.3078","days":"14","issn":"2168-6068","rank":"10","field":"Clinical Medicine","score":"26","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.3078","title":"Local Recurrence and Survival in Patients With Melanoma In Situ.","journal":"JAMA dermatology","methods":"","results":"$30","abstract":"$31","keywords":[],"pubmed_id":"40900523","conclusions":"","publication_date":"2025-09-03T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.3078","URL":"https://doi.org/10.1001/jamadermatol.2025.3078","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2838218/jamadermatology_dessinioti_2025_oi_250043_1760475168.3899.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"1002","type":"journal-article","issue":"10","score":1,"title":["Local Recurrence and Survival in Patients With Melanoma In Situ"],"author":[{"given":"Clio","family":"Dessinioti","sequence":"first","affiliation":[{"name":"First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athens, Greece"}]},{"given":"Aggeliki","family":"Befon","sequence":"additional","affiliation":[{"name":"State Department of Dermatology-Venereology, Andreas Sygros Hospital, Athens, Greece"}]},{"given":"Mihaella","family":"Plaka","sequence":"additional","affiliation":[{"name":"First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athens, Greece"}]},{"given":"Aikaterini","family":"Niforou","sequence":"additional","affiliation":[{"name":"First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athens, Greece"}]},{"given":"Katerina","family":"Kypreou","sequence":"additional","affiliation":[{"name":"First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athens, Greece"}]},{"given":"Alan C.","family":"Geller","sequence":"additional","affiliation":[{"name":"Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"}]},{"given":"Alexander J.","family":"Stratigos","sequence":"additional","affiliation":[{"name":"First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athens, Greece"}]}],"issued":{"date-parts":[[2025,10,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"161","created":{"date-time":"2025-09-03T15:00:55Z","timestamp":1756911655000,"date-parts":[[2025,9,3]]},"indexed":{"date-time":"2025-10-16T00:51:10Z","timestamp":1760575870867,"date-parts":[[2025,10,16]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2838218"}},"subtitle":[],"deposited":{"date-time":"2025-10-15T15:02:23Z","timestamp":1760540543000,"date-parts":[[2025,10,15]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,10,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1016/j.ejca.2024.115153","key":"doi250043r1","year":"2025","issue":null,"author":"Garbe","volume":"215","first-page":null,"unstructured":null,"article-title":"European consensus-based interdisciplinary guideline for melanoma. part 2: treatment: update 2024.","journal-title":"Eur J Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.05.011","key":"doi250043r3","year":"2016","issue":"4","author":"Wei","volume":"75","first-page":"698","unstructured":null,"article-title":"Trends in the diagnosis and clinical features of melanoma in situ (MIS) in US men and women: a prospective, observational study.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljae175","key":"doi250043r4","year":"2024","issue":"3","author":"Nielsen","volume":"191","first-page":"365","unstructured":null,"article-title":"Increasing melanoma incidence with unchanged mortality: more sunshine, better treatment, increased diagnostic activity, overdiagnosis or lowered diagnostic threshold?","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2023.1494","key":"doi250043r5","year":"2023","issue":"7","author":"Patel","volume":"159","first-page":"703","unstructured":null,"article-title":"Risk of mortality after a diagnosis of melanoma in situ.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljad033","key":"doi250043r6","year":"2023","issue":"6","author":"van Bodegraven","volume":"188","first-page":"777","unstructured":null,"article-title":"‘Get data out’ skin: national cancer registry incidence and survival rates for all registered skin tumour groups for 2013-2019 in England.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMsb2019760","key":"doi250043r7","year":"2021","issue":"1","author":"Welch","volume":"384","first-page":"72","unstructured":null,"article-title":"The rapid rise in cutaneous melanoma diagnoses.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljae296","key":"doi250043r8","year":"2024","issue":"6","author":"Lindsay","volume":"191","first-page":"906","unstructured":null,"article-title":"Estimating the magnitude and healthcare costs of melanoma in situ and thin invasive melanoma overdiagnosis in Australia.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1002/pon.4366","key":"doi250043r9","year":"2017","issue":"11","author":"Bell","volume":"26","first-page":"1784","unstructured":null,"article-title":"Fear of new or recurrent melanoma after treatment for localised melanoma.","journal-title":"Psychooncology","doi-asserted-by":"publisher"},{"DOI":"10.1097/CMR.0000000000001007","key":"doi250043r10","year":"2025","issue":"1","author":"Zheng","volume":"35","first-page":"11","unstructured":null,"article-title":"Psychosocial wellbeing in people with melanoma in-situ: a systematic review.","journal-title":"Melanoma Res","doi-asserted-by":"publisher"},{"DOI":"10.1111/ddg.15699","key":"doi250043r11","year":"2025","issue":"7","author":"Dessinioti","volume":"23","first-page":"805","unstructured":null,"article-title":"Local recurrence of non-lentigo maligna melanoma in situ and safety excision margins: A systematic review.","journal-title":"J Dtsch Dermatol Ges","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ejca.2022.04.018","key":"doi250043r12","year":"2022","issue":null,"author":"Garbe","volume":"170","first-page":"256","unstructured":null,"article-title":"European consensus-based interdisciplinary guideline for melanoma. part 2: treatment - update 2022.","journal-title":"Eur J Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2024.1878","key":"doi250043r14","year":"2024","issue":"8","author":"Sun","volume":"160","first-page":"874","unstructured":null,"article-title":"Recurrence rate of small melanoma in situ on low-risk sites excised with 5-mm excisional margin.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2021.04.090","key":"doi250043r15","year":"2021","issue":"3","author":"Bittar","volume":"85","first-page":"681","unstructured":null,"article-title":"Systematic review and meta-analysis of local recurrence rates of head and neck cutaneous melanomas after wide local excision, Mohs micrographic surgery, or staged excision.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1097/DSS.0000000000003683","key":"doi250043r16","year":"2023","issue":"2","author":"Campbell","volume":"49","first-page":"119","unstructured":null,"article-title":"Local recurrence rates of malignant melanoma after Mohs micrographic surgery are lowest with 5- to 10-mm initial margins: a systematic review and meta-analysis.","journal-title":"Dermatol Surg","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdin.2022.06.001","key":"doi250043r17","year":"2022","issue":null,"author":"Gaetano","volume":"8","first-page":"102","unstructured":null,"article-title":"Association between excision margins and local recurrence in 1407 patients with primary in situ melanomas.","journal-title":"JAAD Int","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljad031","key":"doi250043r18","year":"2023","issue":"5","author":"Smith","volume":"188","first-page":"685","unstructured":null,"article-title":"Is it time we changed the way we manage melanoma in situ of the trunk and limbs?","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1097/DSS.0000000000002417","key":"doi250043r19","year":"2021","issue":"1","author":"Daniel","volume":"47","first-page":"1","unstructured":null,"article-title":"Recurrence and mortality of melanoma in situ of the trunk or extremities: a surveillance, epidemiology, and end results analysis.","journal-title":"Dermatol Surg","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2016.6138","key":"doi250043r20","year":"2017","issue":"5","author":"Nosrati","volume":"153","first-page":"436","unstructured":null,"article-title":"Outcomes of melanoma in situ treated with Mohs micrographic surgery compared with wide local excision.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.bjps.2013.11.014","key":"doi250043r21","year":"2014","issue":"3","author":"Akhtar","volume":"67","first-page":"320","unstructured":null,"article-title":"Surgical excision margins for melanoma in situ.","journal-title":"J Plast Reconstr Aesthet Surg","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2023.1485","key":"doi250043r22","year":"2023","issue":"7","author":"Cust","volume":"159","first-page":"699","unstructured":null,"article-title":"Melanoma in situ-getting the diagnosis and prognosis right.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2017.6448","key":"doi250043r23","year":"2018","issue":"4","author":"Nufer","volume":"154","first-page":"398","unstructured":null,"article-title":"Dermoscopy and overdiagnosis of melanoma in situ.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0046-8177(96)90157-4","key":"doi250043r24","year":"1996","issue":"6","author":"Farmer","volume":"27","first-page":"528","unstructured":null,"article-title":"Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists.","journal-title":"Hum Pathol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2022.50613","key":"doi250043r25","year":"2023","issue":"1","author":"Barnhill","volume":"6","first-page":null,"unstructured":null,"article-title":"Revision of the melanocytic pathology assessment tool and hierarchy for diagnosis classification schema for melanocytic lesions: a consensus statement.","journal-title":"JAMA Netw Open","doi-asserted-by":"publisher"},{"DOI":"10.1093/jnci/djac138","key":"doi250043r26","year":"2022","issue":"10","author":"Olsen","volume":"114","first-page":"1364","unstructured":null,"article-title":"Incidence of in situ vs invasive melanoma: testing the “obligate precursor” hypothesis.","journal-title":"J Natl Cancer Inst","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.18453","key":"doi250043r27","year":"2022","issue":"11","author":"Dessinioti","volume":"36","first-page":"1927","unstructured":null,"article-title":"A review of nevus-associated melanoma: what is the evidence?","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.19819","key":"doi250043r28","year":"2021","issue":"1","author":"Dessinioti","volume":"185","first-page":"101","unstructured":null,"article-title":"A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0046-8177(84)80310-X","key":"doi250043r29","year":"1984","issue":"12","author":"Clark","volume":"15","first-page":"1147","unstructured":null,"article-title":"A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma.","journal-title":"Hum Pathol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1502583","key":"doi250043r30","year":"2015","issue":"20","author":"Shain","volume":"373","first-page":"1926","unstructured":null,"article-title":"The genetic evolution of melanoma from precursor lesions.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ccell.2018.06.005","key":"doi250043r31","year":"2018","issue":"1","author":"Shain","volume":"34","first-page":"45","unstructured":null,"article-title":"Genomic and transcriptomic analysis reveals incremental disruption of key signaling pathways during melanoma evolution.","journal-title":"Cancer Cell","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2015.3775","key":"doi250043r32","year":"2016","issue":"3","author":"Haenssle","volume":"152","first-page":"291","unstructured":null,"article-title":"Association of patient risk factors and frequency of nevus-associated cutaneous melanomas.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2017.12.036","key":"doi250043r33","year":"2018","issue":"8","author":"Pandeya","volume":"138","first-page":"1816","unstructured":null,"article-title":"Factors related to nevus-associated cutaneous melanoma: a case-case study.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/archderm.139.3.282","key":"doi250043r34","year":"2003","issue":"3","author":"Tsao","volume":"139","first-page":"282","unstructured":null,"article-title":"The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate.","journal-title":"Arch Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.21010","key":"doi250043r35","year":"2022","issue":"6","author":"Semsarian","volume":"186","first-page":"1030","unstructured":null,"article-title":"Do we need to rethink the diagnoses melanoma in?situ and severely dysplastic naevus?","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0046-8177(06)80029-8","key":"doi250043r36","year":"1990","issue":"12","author":"Clark","volume":"21","first-page":"1197","unstructured":null,"article-title":"Malignant melanoma in situ.","journal-title":"Hum Pathol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2008.08994.x","key":"doi250043r37","year":"2009","issue":"4","author":"Dauendorffer","volume":"160","first-page":"810","unstructured":null,"article-title":"Shrinkage of skin excision specimens: formalin fixation is not the culprit.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1245/s10434-018-6858-y","key":"doi250043r38","year":"2019","issue":"1","author":"Friedman","volume":"26","first-page":"25","unstructured":null,"article-title":"Correlation between surgical and histologic margins in melanoma wide excision specimens.","journal-title":"Ann Surg Oncol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi250043r2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Swetter? SM, Johnson? D, Albertini? MR, . National Comprehensive Cancer Network Guidelines. Melanoma: cutaneous. version 2.2025—January 28, 2025. Accessed on February 15, 2025. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1492","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250043r13","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Strengthening the reporting of observational studies in epidemiology: STROBE checklists. Accessed on November 24, 2023. https://www.strobe-statement.org/checklists/","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2025,10,1]]},"reference-count":38,"published-online":null,"references-count":38,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1001/jamadermatol.2025.3078","is_oa":false,"title":"Local Recurrence and Survival in Patients With Melanoma In Situ","updated":"2025-09-04T02:50:00+00:00","published_date":"2025-09-03","best_oa_location":null}},"created_at":"2025-10-21T07:06:57.272Z","updated_at":"2025-10-30T07:01:44.795Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.3078","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3078","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3078","tag_type":"condition","value":"Melanoma In Situ","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3078","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3078","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3078","tag_type":"modality","value":"Surgery","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3078","tag_type":"sample_size","value":"n=401","value_numeric":401},{"paper_doi":"10.1001/jamadermatol.2025.3078","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3078","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3078","tag_type":"warning","value":"Outcomes are reported both per lesion and per patient; denominators vary.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3078","tag_type":"warning","value":"Single-center cohort; generalizability may be limited.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3078","tag_type":"warning","value":"Subgroup findings (no wide excision and narrow margins) are based on small numbers.","value_numeric":null}],"summaries":{"what_studied":"Retrospective cohort of patients with non–lentigo maligna/non–acral lentiginous melanoma in situ (401 patients, 403 lesions) managed at a single center from 1991–2023 (median follow-up 5.2 years), assessing local recurrence, metastasis, and melanoma-specific survival by excisional biopsy margin status and wide-excision margin size.","key_result":"Only 1 local recurrence occurred, in a case with involved biopsy margins and no wide excision, progressing to invasive melanoma at 14 months; there were 0 metastases and 0 melanoma-specific deaths. Among 30 lesions with clear biopsy margins and no wide excision, there were 0 recurrences at a median 8.1 years; among 23 lesions excised with <0.5-cm margins (mean 0.36 cm), there were 0 recurrences at a median 4.3 years.","limitations":"Single-center, retrospective design with small subgroup sizes for no–wide excision (n=30) and narrow-margin (n=23) cohorts. Findings apply only to non-LM/non-ALM melanoma in situ.","practice_takeaway":"For non-LM/non-ALM melanoma in situ, clear margins on diagnostic excisional biopsy were associated with no observed local recurrences without further surgery, and narrower-than-standard wide-excision margins also showed no recurrences in small numbers. Consider these data hypothesis-generating; larger studies are needed and current standards should guide care."}}],"initialOffset":7,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Melanoma In Situ"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Melanoma In Situ"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Melanoma In Situ"}}}]]

Papers